New perspectives in the therapeutic approach of peripheral T-cell lymphoma.

Abstract

PURPOSE OF REVIEW:

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell and natural killer (NK)-cell neoplasms in the WHO 2016 classification. Patient prognosis is poor when treated with CHOP, and there is an unmet need for new drugs. Several agents have been developed for PTCL, and their use is the subject of this review.

RECENT FINDINGS:

Phase 2 studies demonstrated the activity of new drugs in Relapsed/refractory PTCL. Only four compounds were approved by the food and drug administration: romidepsin and belinostat, which are epigenetic modifiers, the antifolate agent pralatrexate, the immuno-conjugate brentuximab vedotin. New combinations have been tested, but the results were disappointing. Given the latest progress in biology, targeted agents are evaluated in different subtypes of PTCL. Relapsed anaplastic large-cell lymphoma exhibits improved prognosis with the approved anti-CD30 drug conjugate brentuximab vedotin. Localized nasal NK/T is treated with radiotherapy and nonanthracycline chemotherapy with L-asparaginase. Recently, immune checkpoint inhibitors demonstrated activity in NK/T lymphoma and can be used in elderly patients.

SUMMARY:

Treatment remains a challenge for PTCL, and several targeted drugs provide new approaches. Progress will be made incrementally in the different subtypes. One of the critical situations facing new drugs is the ability to run robust clinical trials in rare diseases.

• Authors: Christian Gisselbrecht, David Sibon
• Journal: Current opinion in oncology (Curr Opin Oncol) Vol. 30 Issue 5 Pg. 285-291 (09 2018) ISSN: 1531-703X [Electronic] United States
• PMID: 30096094 (Publication Type: Journal Article, Review)

Chemical References

• 10-propargyl-10-deazaaminopterin
• Depsipeptides
• Hydroxamic Acids
• Immunoconjugates
• Sulfonamides
• Brentuximab Vedotin
• romidepsin
• belinostat
• Aminopterin

Topics

• Aminopterin (administration & dosage, analogs & derivatives)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Brentuximab Vedotin
• Clinical Trials, Phase II as Topic
• Depsipeptides (administration & dosage)
• Humans
• Hydroxamic Acids (administration & dosage)
• Immunoconjugates (administration & dosage)
• Lymphoma, T-Cell, Peripheral (drug therapy, immunology, radiotherapy, therapy)
• Randomized Controlled Trials as Topic
• Sulfonamides (administration & dosage)